Pharmacogenetics: Using Genetic Information to Guide Drug Therapy

Area of Science:

• Pharmacogenetics
• Genetics
• Drug Metabolism

Background:

• Clinical pharmacogenetics is increasingly relevant for primary care medications.
• Many clinicians lack familiarity with the principles of pharmacogenetics.
• Genetic variations in drug-metabolizing enzymes like CYP2D6 and CYP2C19 impact drug efficacy and safety.

Purpose of the Study:

• To highlight the growing importance of clinical pharmacogenetics in family medicine.
• To explain how genetic variations affect common drug therapies.
• To inform clinicians about practical applications and emerging resources in pharmacogenetics.

Main Methods:

• Review of existing literature and guidelines on pharmacogenetics.
• Identification of key drug-metabolizing enzymes (CYP2D6, CYP2C19) and their associated medications (opioids, clopidogrel).
• Analysis of clinical implications for different genetic metabolizer statuses (ultrarapid, poor).

Main Results:

• CYP2D6 variations affect opioid metabolism (codeine, tramadol), necessitating dose adjustments or avoidance in poor/ultrarapid metabolizers.
• CYP2C19 variations impact clopidogrel effectiveness, requiring alternative antiplatelet therapy (ticagrelor, prasugrel) in poor metabolizers undergoing PCI.
• Guidelines and clinical resources are emerging to support pharmacogenetic implementation.

Conclusions:

• Pharmacogenetic testing offers a practical approach to optimize drug therapy.
• Tailoring medication based on genetic profiles can prevent adverse drug reactions and improve treatment effectiveness.
• Further integration of pharmacogenetics into clinical practice is recommended for family physicians.